Genmab DARZALEX Q3 2026 Net Sales Reach $4.2 Billion

Key Facts

1Total worldwide net trade sales of DARZALEX in Q3 2026 amounted to USD 4,239 million.

2Sales were distributed as USD 2,528 million in the U.S. and USD 1,711 million in the rest of the world.

3Genmab receives royalties on worldwide net sales reported by Johnson & Johnson.

Genmab announced that total worldwide net trade sales of DARZALEX amounted to USD 4,239 million in the third quarter of 2026. GlobeNewswire reported that sales were distributed as USD 2,528 million in the U.S. and USD 1,711 million in the rest of the world. Genmab receives royalties on these worldwide net sales reported by its partner Johnson & Johnson under an exclusive license agreement.

GMAB closed at $37.37 on October 12, 2026, while JNJ closed at $263.73 on the same date. These strong sales figures for the core product support Genmab's royalty revenue stream, reflecting sustained global demand for both the intravenous and subcutaneous versions of the treatment.